FDA clears Roche, Eli Lilly Alzheimer's blood test

• The test can run on over 4,500 Roche laboratory analyzers already installed across the U.S., potentially broadening access to Alzheimer's screening
• Current detection methods for amyloid protein are expensive, invasive, and less widely available compared to this blood-based biomarker test
• The test is not intended as a standalone diagnostic tool and must be interpreted alongside other clinical information; pricing was not disclosed

Summary

FDA Clears Roche-Eli Lilly Alzheimer's Blood Test

The U.S. Food and Drug Administration has approved a blood test developed by Roche and Eli Lilly to help identify signs of Alzheimer's disease in patients aged 55 and older experiencing cognitive decline. The test, called Elecsys pTau217, is a biomarker blood test that helps physicians determine whether patients likely have Alzheimer's-related brain changes.

Key Details:

• The FDA clearance follows European approval in May 2024
• The test can be run on over 4,500 Roche laboratory analyzers already installed across the United States
• Major diagnostic companies Labcorp and Quest Diagnostics plan to offer the test through their laboratory networks
• Pricing was not disclosed by Roche

Market Context:

This approval represents a significant advancement in Alzheimer's diagnostics, as current detection methods typically rely on expensive and invasive procedures like PET scans or cerebrospinal fluid testing. The new blood test offers a simpler, more accessible alternative.

The clearance comes during an industry race to develop easier Alzheimer's testing methods, driven by growing demand for earlier diagnosis and treatment. Elecsys pTau217 became the first blood test cleared by the FDA for Alzheimer's assessment in 2025.

Important Limitations:

Roche emphasized that the test is not intended as a standalone diagnostic tool and results must be interpreted alongside other clinical information.

Market Implications:

The widespread availability through existing infrastructure could significantly broaden access to Alzheimer's screening, potentially accelerating early detection and treatment initiation across the United States.